EnteroMedics® Inc. has developed VBLOC® vagal blocking therapy, a first-in-class weight loss treatment for obesity and related co-morbidities. VBLOC Therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, is designed to control both hunger and fullness by blocking the primary nerve which regulates the digestive system. VBLOC Therapy is designed to address the lifelong challenge of obesity by empowering people to take a positive path toward weight loss without compromising their lifestyle.

NASDAQ: ETRM

EnteroMedics has significant experience with VBLOC Therapy; more than 600 patients have been implanted with the Maestro System to date, some out to five years.

At EnteroMedics, partnerships are viewed as an excellent approach for achieving our business objectives, and we are interested in hearing from you.

learn more >

February 21, 2012
EnteroMedics to Participate in 4th Annual Lazard Capital Markets Medical Technology Conference

learn more >